MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

liver
Biotech

Madrigal pens $4.4B deal for siRNA drugs in fresh Rezdiffra play

Madrigal is continuing to splash the cash this year on liver disease drugs it can combine with its own potential blockbuster Rezdiffra.
James Waldron Feb 11, 2026 7:40am
target reach ladder climb meet win beat competition

OrsoBio hits target in midstage study for metabolic conditions

Feb 10, 2026 8:00am
liver

Madrigal pays Pfizer $50M for MASH drug with combo potential

Jan 9, 2026 10:50am
obesity overweight weight loss weigh

MetaVia weighs in with 9% loss to enter the obesity ring

Jan 5, 2026 10:44am
person throwing away garbage or recycling

After $4.8B Amicus buy, BioMarin drops genetic disease asset

Dec 22, 2025 11:12am
next step ladder climb succeed win

Altimmune eyes phase 3 MASH trial as weight loss deepens

Dec 19, 2025 8:30am